+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastric Cancer Drugs Global Market Report 2022, Type, End User, Route of Administration

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5559801
Gastric Cancer Drugs Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global gastric cancer drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the gastric cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Gastric Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:
1) By Type: Doxorubicin Hydrochloride; Sunitinib; Docetaxel; Mitomycin; Fluorouracil; Imatinib; Trastuzumab
2) By End User: Hospitals; Clinics; Others
3) By Route of Administration: Oral; Parenteral

Companies Mentioned: Eli Lilly and company; Novartis; Merck KGaA; Otsuka Pharmaceutical; F.Hoffmann-La Roche

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary2. Gastric Cancer Drugs Market Characteristics3. Gastric Cancer Drugs Market Trends And Strategies4. Impact Of COVID-19 On Gastric Cancer Drugs
5. Gastric Cancer Drugs Market Size And Growth
5.1. Global Gastric Cancer Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Gastric Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Gastric Cancer Drugs Market Segmentation
6.1. Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Doxorubicin Hydrochloride
  • Sunitinib
  • Docetaxel
  • Mitomycin
  • Fluorouracil
  • Imatinib
  • Trastuzumab
6.2. Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals
  • Clinics
  • Others
6.3. Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oral
  • Parenteral

7. Gastric Cancer Drugs Market Regional And Country Analysis
7.1. Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Gastric Cancer Drugs Market
8.1. Asia-Pacific Gastric Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Gastric Cancer Drugs Market
9.1. China Gastric Cancer Drugs Market Overview
9.2. China Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Gastric Cancer Drugs Market
10.1. India Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Gastric Cancer Drugs Market
11.1. Japan Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Gastric Cancer Drugs Market
12.1. Australia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Gastric Cancer Drugs Market
13.1. Indonesia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Gastric Cancer Drugs Market
14.1. South Korea Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Gastric Cancer Drugs Market
15.1. Western Europe Gastric Cancer Drugs Market Overview
15.2. Western Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Gastric Cancer Drugs Market
16.1. UK Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Gastric Cancer Drugs Market
17.1. Germany Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Gastric Cancer Drugs Market
18.4. France Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Gastric Cancer Drugs Market
19.1. Eastern Europe Gastric Cancer Drugs Market Overview
19.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Gastric Cancer Drugs Market
20.1. Russia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Gastric Cancer Drugs Market
21.1. North America Gastric Cancer Drugs Market Overview
21.2. North America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Gastric Cancer Drugs Market
22.1. USA Gastric Cancer Drugs Market Overview
22.2. USA Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Gastric Cancer Drugs Market
23.1. South America Gastric Cancer Drugs Market Overview
23.2. South America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Gastric Cancer Drugs Market
24.1. Brazil Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Gastric Cancer Drugs Market
25.1. Middle East Gastric Cancer Drugs Market Overview
25.2. Middle East Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Gastric Cancer Drugs Market
26.1. Africa Gastric Cancer Drugs Market Overview
26.2. Africa Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Gastric Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Gastric Cancer Drugs Market Competitive Landscape
27.2. Gastric Cancer Drugs Market Company Profiles
27.2.1. Eli Lilly and company
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Novartis
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Merck KGaA
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Otsuka Pharmaceutical
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. F. Hoffmann-La Roche
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Gastric Cancer Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market30. Gastric Cancer Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the gastric cancer drugs market are Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche, GlaxoSmithKline PLC, Bristol-Myers Squibb, Sanofi, Pfizer Inc., AstraZeneca, Bayer Healthcare, Abbott, AROG Pharmaceuticals, Ipsen Biopharmaceuticals, Array Biopharma, Taiho Oncology, AstraZeneca, ARIAD Pharmaceuticals, Ono Pharmaceutical, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, Imugene Limited, Boehringer Ingelheim, Daiichi-Sankyo and Danaher corporation.

The global gastric cancer drugs market is expected to grow from $2.63 billion in 2021 to $3.05 billion in 2022 at a compound annual growth rate (CAGR) of 15.9%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.18 billion in 2025 at a CAGR of 14.2%.

The gastric cancer drugs market consists of sales of drugs for gastric cancer. Gastric cancer, also known as stomach cancer, is the formation of abnormal cells on the lining of stomach resulting in stomach pain and indigestion.

The main types of gastric cancer drugs are doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib and trastuzumab. Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumour (GIST). The drugs are administered through oral and parenteral that are used by hospitals, clinics, and others

North America was the largest region in the gastric cancer drugs market in 2021. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increasing number of obesity cases and smoking population increased number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to the estimates of American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.

Stringent regulations and policies for approval of the drugs restrain the market for gastric cancer drugs. Different regions have their own set of rules, guidelines and regulations set by their respective drugs regulation board. For example, the USFDA regulations for American pharmaceuticals states various conditions with regards to safety and effectiveness of the drug as well as certain labeling requirements. Similarly, the European medicines agency (EMA) gives licenses to the approved drugs before they can be marketed or commercialized in the European continent. Teysuno, a drug for advanced gastric cancer can be only obtained through a valid prescription and the protocol is that every company must assess the effects of using Teysuno and must list out the precautions to be taken by patients and healthcare providers to minimize any possible side effects. These regulations hinder the growth of the gastric cancer drugs market.

Many companies are using combination therapies to cure gastric cancer. Combination therapies help in treating patients with two or more drugs for a single disease and help in better treating the patients. For instance, in 2019, the USFDA has approved Taiho Oncology Inc’s combined product LONSURF trifluridine/tipiracil for pre-treated metastatic gastric cancer. This approval is significant for patients living with advanced gastric or GEJ (gastroesophageal junction) adenocarcinoma who have limited effective treatment options after failure of standard treatment options. Advances in the drugs for treatment of gastric cancer will have a positive influence on the gastric cancer drugs’ market

The gastric cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, FDA's Current Good Manufacturing Practice (CGMP) regulation lays down minimum requirements for the methods and facilities used in manufacturing, processing, and packing of a drug product and ensures the quality of drugs produced by manufacturers. Moreover, FDA's guidance provides recommendations to applicants for cancer clinical trials and shows support in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications.

On April 2019, AstraZeneca, a multinational pharmaceutical and biopharmaceutical company acquired Daiichi Sankyo for $1.35 billion. This acquisition will help AstraZeneca to jointly develop drug Trastuzumab Deruxtecan with Daiichi Sankyo. This drug would help to treat people suffering from breast and gastric cancer. Daiichi Sankyo headquarted at Japan is a global pharmaceutical company which offers innovative products and a robust pipeline for cancer treatment.

The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lilly and company
  • Novartis
  • Merck KGaA
  • Otsuka Pharmaceutical
  • F.Hoffmann-La Roche
  • GlaxoSmithKline PLC.
  • Bristol-Myers Squibb
  • Sanofi
  • Pfizer Inc.
  • AstraZeneca
  • Bayer Healthcare
  • Abbott
  • AROG Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • Array Biopharma
  • Taiho Oncology
  • AstraZeneca
  • ARIAD Pharmaceuticals
  • Ono Pharmaceutical
  • Jiangsu HengRui Medicine
  • Gilead Bioscience
  • Celgene/Taiho
  • Boston Biomedical
  • Imugene Limited
  • Boehringer Ingelheim
  • Daiichi-Sankyo
  • Danaher corporation

Methodology

Loading
LOADING...